Results 1 to 10 of about 4,667 (238)

Targeting Bruton’s Tyrosine Kinase in CLL [PDF]

Frontiers in Immunology, 2021
Targeting the B-cell receptor signaling pathway through BTK inhibition proved to be effective for the treatment of chronic lymphocytic leukemia (CLL) and other B-cell lymphomas.
Inhye E. Ahn, Jennifer R. Brown
doaj   +4 more sources

Efficacy and safety of Bruton's tyrosine kinase inhibitors in the treatment of pemphigus: A comprehensive literature review and future perspective [PDF]

Heliyon, 2023
Bruton's tyrosine kinase (BTK) is a protein involved in B-cell-receptor signaling and B-cell proliferation. The pathophysiology of several autoimmune diseases, such as pemphigus disorder, relies on the BTK signaling pathway.
Yekta Ghane, Nazila Heidari, Amirhossein Heidari, Sara Sadeghi, Azadeh Goodarzi   +4 more
doaj   +2 more sources

Development of a Partial Proteolysis Targeting Chimera Library Based on Achiral Cereblon E3 Ligase Ligands and its Application for Bruton's Tyrosine Kinase Degraders. [PDF]

ChemMedChem
A partial proteolysis targeting chimera (PROTAC) library bearing achiral phenyl dihydrouracil cereblon ligands is prepared. It is then applied to the rapid development of a full PROTAC library targeting Bruton's tyrosine kinase, which can be directly used for screening.
Almodóvar-Rivera CM, Tandon I, Mudududdla R, Esguerra PN, Lucio-Acero K, Tang W.   +5 more
europepmc   +2 more sources

A novel Bruton's tyrosine kinase inhibitor JDB175 shows potent efficacy to suppress central nervous system lymphoma [PDF]

MedComm, 2023
Patients with central nervous system (CNS) lymphoma face limited treatment options and poor treatment outcomes, emphasizing the urgent need for effective therapeutic strategies.
Yong Xia, Xue Li, Ning Jiang, Xiawei Wei
doaj   +2 more sources

A review of Bruton’s tyrosine kinase inhibitors in multiple sclerosis [PDF]

Therapeutic Advances in Neurological Disorders
Bruton’s tyrosine kinase (BTK) inhibitors are an emerging class of therapeutics in multiple sclerosis (MS). BTK is expressed in B-cells and myeloid cells, key progenitors of which include dendritic cells, microglia and macrophages, integral effectors of ...
Laura Airas, Robert A. Bermel, Tanuja Chitnis, Hans-Peter Hartung, Jin Nakahara, Olaf Stuve, Mitzi J. Williams, Bernd C. Kieseier, Heinz Wiendl   +8 more
doaj   +2 more sources

Bruton’s tyrosine kinase is a possible therapeutic target in microscopic polyangiitis [PDF]

Arthritis Research & Therapy, 2023
Background Bruton’s tyrosine kinase (Btk) is an enzyme expressed in leukocytes other than T lymphocytes and plasma cells and involved in B-cell receptor- and Fcγ receptor (FcγR)-mediated signal transduction.
Issei Nakade, Yuto Tamura, Fuyu Hashimoto, Yuko Ariza, Shingo Hotta, Hirofumi Fujigaya, Suishin Arai, Mai Taniguchi, Hodaka Ogawa, Yuka Nishibata, Sakiko Masuda, Daigo Nakazawa, Utano Tomaru, Akihiro Ishizu   +13 more
doaj   +2 more sources

Novel Bruton's tyrosine kinase inhibitor TAS5315 suppresses the progression of inflammation and joint destruction in rodent collagen-induced arthritis.

PLoS ONE, 2023
Rheumatoid arthritis is an inflammatory autoimmune disease, characterized by autoantibody production, synovial inflammation, and joint destruction. Its pathogenesis is due to environmental factors and genetic backgrounds.
Daichi Akasaka, Satoru Iguchi, Ryusuke Kaneko, Yohei Yoshiga, Daisuke Kajiwara, Yoshinori Nakachi, Naruto Noma, Kenji Tanaka, Atsushi Shimizu, Fumihito Hosoi   +9 more
doaj   +2 more sources

ASK120067 potently suppresses B-cell or T-cell malignancies in vitro and in vivo by inhibiting BTK and ITK

Frontiers in Pharmacology, 2022
Hyperactivation of Bruton’s tyrosine kinase (BTK) or interleukin-2-inducible T cell kinase (ITK) has been attributed to the pathogenesis of B-cell lymphoma or T-cell leukemia, respectively, which suggests that Bruton’s tyrosine kinase and interleukin-2 ...
Peiran Song, Peiran Song, Gang Bai, Shingpan Chan, Tao Zhang, Linjiang Tong, Yi Su, Yanyan Shen, Yi Chen, Yingqiang Liu, Mengzhen Lai, Mengzhen Lai, Yi Ning, Haotian Tang, Yan Fang, Yi Chen, Ke Ding, Jian Ding, Jian Ding, Hua Xie, Hua Xie, Hua Xie   +21 more
doaj   +1 more source

Bruton’s tyrosine kinase inhibitor associated localized extremity edema and erythema [PDF]

JAAD Case Reports
Shannon Meledathu, BS, Paul Chu, MD, Tatyana Feldman, MD, Andre Henri Goy, MD, Rachel Kushner Rosenstein, MD, PhD   +4 more
doaj   +2 more sources

Disrupting enzyme fluidity

eLife, 2021
A combination of X-ray crystallography, NMR, and mass spectrometry has revealed how diverse small-molecule inhibitors bind Bruton’s tyrosine kinase and alter the conformation of this enzyme.
Ganesh Srinivasan Anand
doaj   +1 more source